A predictable as well as precise effect, possibly conferring an extraordinarily sustained disease remission, by disabling the CD40 ligand (CD40L) (having nonredundant and far-reaching immunoregulatory effects) has recently been documented in SLE, SjD and MS patients (42). The gene discussed is CD40LG; the disease is myeloid sarcoma.